ABSTRACT
Objective:To evaluate the therapeutic efficacy and side effects of P-Gemox regimen combined with intensity modulated radiotherapy in the treatment of extranodal NK/T cell lymphoma, nasal type (ENKTL).Methods:The data of 60 patients with ENKTL confirmed by pathomorphology and immunohistochemistry in Guizhou Cancer Hospital from July 2014 to October 2019 were retrospectively analyzed. All patients received P-Gemox chemotherapy combined with intensity modulated radiotherapy (at least 2 cycles), and the efficacy and adverse reactions were evaluated.Results:The complete remission rate of 60 patients was 65.0% (39/60), the partial remission rate was 25.0% (15/60), and the total effective rate was 90.0% (54/60). The main side reactions were myelosuppression, transaminase elevation and radiation mucositis; most of them were mild to moderate, which were relieved after treatment or the withdrawal of radiotherapy and chemotherapy. No treatment-related death cases were found. The overall survival rate of 1-year, 2-year, 3-year was 91%, 75% and 69%; the progression-free survival rate of 1-year, 2-year, 3-year was 86%, 68% and 62%. During the treatment, 3 cases died due to the progress of the disease and infection. Multivariate analysis showed that with and without hemophagocytic syndrome and radiotherapy dose were related to prognosis (all P < 0.05). Conclusion:P-Gemox, as the first-line induction chemotherapy regimen combined with intensity modulated radiotherapy has good short-term efficacy and safety for patients with ENKTL.
ABSTRACT
The extensive application of radiotherapy and the long survival of patients with malignant tumors have led to an in-creased incidence rate of radiation-induced osteosarcoma (RIOS), one of the most critical radiation-induced complications. Compared with primary osteosarcoma, RIOS has higher grade and poorer prognosis, which reduces the survival of patients with cancers. However, RIOS has not been fully understood in the clinical setting. This paper summarizes the latest progress at home and abroad, focusing on the incidence rate, risk factor, latency, and diagnostic criteria of RIOS. The molecular mechanism of RIOS is associated with the muta-tion of p53, the activation of the Wnt/β-catenin signaling pathway, and the superposition of multiple alleles. Furthermore, we discuss the differences in clinical characteristics, imaging findings, treatment, and prognosis between primary osteosarcoma and RIOS.